Group 1 - The stock of Kaili Medical (300633) closed at 32.33 yuan on September 5, 2025, with an increase of 2.31% and a trading volume of 31,200 hands, totaling 100 million yuan in transaction value [1] - On September 5, the net outflow of main funds was 1.5851 million yuan, accounting for 1.58% of the total transaction value, while the net inflow of speculative funds was 2.8629 million yuan, accounting for 2.86% [1] - The company's main business includes the independent research, development, production, and sales of medical diagnostic and treatment equipment [2] Group 2 - Kaili Medical's total market value is 13.99 billion yuan, which is higher than the industry average of 11.933 billion yuan, ranking 25th out of 123 in the medical device industry [2] - The company's net profit for the first half of 2025 was 47.03 million yuan, a decrease of 72.43% year-on-year, with a gross profit margin of 62.08% [2] - In the last 90 days, 18 institutions rated the stock, with 12 buy ratings and 6 hold ratings, and the average target price set by institutions is 40.17 yuan [3]

每经AI快讯，开立医疗（SZ 300633，收盘价：32.33元）9月5日晚间发布公告称，公司第四届第十次董 事会会议于2025年9月4日在深圳市光明区光电北路368号开立医疗大厦一楼会议室召开。会议审议了 《关于提请召开2025年第一次临时股东大会的议案》等文件。 2024年1至12月份，开立医疗的营业收入构成为：医疗器械行业占比100.0%。 （记者 张喜威） 截至发稿，开立医疗市值为140亿元。 每经头条（nbdtoutiao）——烤肉店里洗头、西湖边开面包店、进军高端酒店……海底捞"不务正业"背 后：子品牌存活率不足50% ...

Group 1 - The company has confirmed that it meets the qualifications to implement the 2025 restricted stock and stock option incentive plan, as there are no disqualifying conditions outlined in relevant laws and regulations [1][2] - The incentive plan's designated recipients do not fall under any disqualifying conditions specified in the regulations, ensuring their eligibility [2] - The company will publicly disclose the names and positions of the incentive plan recipients for at least 10 days before the shareholders' meeting [3] Group 2 - The formulation and review process of the 2025 incentive plan comply with relevant laws and regulations, ensuring no harm to the interests of the company and its shareholders [3] - There are no plans to provide loans, guarantees, or any financial assistance to the incentive recipients [4] - The implementation of the incentive plan is expected to enhance the company's incentive mechanism, attract and retain talent, and align the interests of shareholders, the company, and employees for long-term development [4]

Core Viewpoint - The company has conducted a review of its 2025 restricted stock and stock option incentive plan, confirming its eligibility to implement the plan in accordance with relevant laws and regulations [2][3][4]. Group 1: Eligibility for Implementation - The company does not fall under any disqualifying conditions for implementing the stock incentive plan as outlined in the relevant regulations [2]. - The company has not received any negative or unqualified audit opinions on its financial reports for the last fiscal year [2]. - There have been no instances of improper profit distribution in the last 36 months [2]. Group 2: Qualification of Incentive Objects - The identified incentive objects do not include independent directors, supervisors, foreign employees, or shareholders holding more than 5% of the company's shares [3]. - All selected incentive objects meet the qualifications set forth in the Company Law and other relevant regulations [3]. - The company will publicly disclose the names and positions of the incentive objects for at least 10 days prior to the shareholders' meeting [3]. Group 3: Compliance and Benefits of the Plan - The drafting and review process of the incentive plan complies with all relevant laws and regulations, ensuring no harm to the interests of the company and its shareholders [4]. - The plan does not involve any financial assistance or guarantees to the incentive objects [4]. - The implementation of the incentive plan aims to establish a long-term incentive mechanism, attract and retain talent, and align the interests of shareholders, the company, and employees [4].

Core Viewpoint - The company has conducted a thorough review of its 2025 Employee Stock Ownership Plan (ESOP) and has determined that it complies with relevant laws and regulations, aiming to enhance employee engagement and long-term value for shareholders [1][2]. Summary by Sections Legal Compliance - The company confirms that there are no prohibitive circumstances under the relevant laws and regulations for implementing the ESOP [1]. - The procedures for drafting the 2025 ESOP and related documents are legal and effective, adhering to the guidelines set forth in the relevant regulatory documents [2]. Employee Engagement - The ESOP has been developed with full consultation from employee representatives, ensuring that the decision-making process is legitimate and does not harm the interests of the company or its shareholders [2]. - Participation in the ESOP is voluntary, with no coercive measures employed to compel employees to join [2]. Benefits of the ESOP - The implementation of the ESOP is expected to foster a mechanism for sharing achievements and risks between talented employees and shareholders, enhancing employee ownership mentality [2]. - The plan aims to optimize the compensation structure and effectively allocate short, medium, and long-term incentive resources to attract, retain, and motivate outstanding talent, thereby promoting the company's long-term stability and increasing shareholder value [2].

Group 1 - The company held its 10th meeting of the 4th Board of Directors on August 29, 2025, with all 7 directors present, meeting the legal requirements [1][2] - The Board approved the draft of the 2025 Employee Stock Ownership Plan (ESOP) to enhance talent retention and align employee interests with shareholder value [2][3] - The voting result for the ESOP was unanimous, with 6 votes in favor and no opposition, representing 100% of the votes cast [3][4] Group 2 - The company plans to implement a 2025 Restricted Stock and Stock Option Incentive Plan to attract and retain talent while ensuring alignment of interests among shareholders, the company, and employees [5][6] - The voting result for the incentive plan was also unanimous, with 6 votes in favor and no opposition, representing 100% of the votes cast [6][7] - The Board proposed to authorize the shareholders' meeting to grant the Board the authority to manage the implementation of the incentive plan, including adjustments based on policy changes [7][8] Group 3 - The company will submit the ESOP and the incentive plan for approval at the upcoming shareholders' meeting [3][4] - The Board will also seek authorization to handle necessary administrative tasks related to the incentive plan, including approvals and registrations with relevant authorities [8][9] - The company aims to ensure the effective implementation of both plans to support its long-term development strategy [5][6]

Core Viewpoint - The Supervisory Board of Shenzhen Kaili Biomedical Technology Co., Ltd. has reviewed the 2025 Employee Stock Ownership Plan and concluded that it complies with relevant laws and regulations, and will not harm the interests of the company or its shareholders [1][2]. Summary by Sections Compliance and Legality - The company does not fall under any prohibitive conditions for implementing the employee stock ownership plan as per the relevant guidelines and regulations [1]. - The procedures for drafting the 2025 Employee Stock Ownership Plan and related documents are legal and effective [2]. Employee Involvement - The plan has been developed with sufficient consultation from employee representatives, ensuring that the decision-making process is legal and does not harm the interests of the company or its shareholders [2]. Eligibility and Benefits - The proposed participants in the employee stock ownership plan meet the eligibility criteria set forth in the relevant guidelines and regulations [2]. - Implementing this plan is expected to foster a mechanism for sharing achievements and risks between talented employees and shareholders, enhancing employee engagement, optimizing compensation structures, and promoting long-term stable development and shareholder value [2].

Group 1 - The company held the ninth meeting of the fourth supervisory board, which was legally valid with all three supervisors present [1] - The supervisory board unanimously approved the 2025 Employee Stock Ownership Plan, confirming its compliance with relevant laws and regulations [2][3] - The board believes that the employee stock ownership plan will enhance corporate governance and create a balanced value distribution system, benefiting the company's sustainable development [2][3] Group 2 - The supervisory board also approved the 2025 Restricted Stock and Stock Option Incentive Plan, which aligns with legal requirements and aims to attract and retain talent [3][4] - The plan is designed to integrate the interests of shareholders, the company, and employees, promoting long-term development without harming the interests of the company and its shareholders [3][4] - The board confirmed that there are no prohibitive circumstances for implementing the incentive plan, and the company is qualified to proceed [3][4] Group 3 - The 2025 Incentive Plan Management Measures were approved to ensure the plan's smooth implementation and compliance with legal standards [4] - The assessment indicators for the incentive plan are deemed scientific and reasonable, aimed at achieving the plan's objectives and enhancing corporate governance [4] - The board will publicly disclose the list of incentive plan participants before the shareholders' meeting, ensuring transparency [6]

Meeting Information - The company will hold its first extraordinary general meeting of shareholders for 2025 on September 23, 2025, at 14:30 [1] - Voting will be conducted both on-site and through an online voting system provided by the Shenzhen Stock Exchange [2] Voting Procedures - Shareholders can choose either on-site voting or online voting, but not both. Duplicate votes will be counted based on the first submission [2][6] - The registration deadline for shareholders is September 17, 2025, at the close of trading [2] Agenda Items - The meeting will discuss several proposals, including the authorization of the board to handle matters related to the 2025 employee stock ownership plan and the 2025 restricted stock and stock option incentive plan [3][4] - Proposals requiring special resolutions need to be approved by more than two-thirds of the voting rights held by attending shareholders [3] Registration and Attendance - Legal representatives of corporate shareholders must present specific documentation to register for the meeting [4][5] - Individual shareholders must also provide identification and shareholder account information for registration [5] Online Voting Process - Detailed procedures for participating in online voting are provided, including the need for identity verification through the Shenzhen Stock Exchange's systems [6]

Group 1 - The core opinion of the legal opinion letter is that the employee stock ownership plan (ESOP) proposed by Shenzhen Kaili Biomedical Technology Co., Ltd. complies with relevant laws and regulations, including the Company Law and Securities Law [2][11][16] - The company has fulfilled the necessary legal procedures for implementing the ESOP, including soliciting employee opinions and obtaining board and supervisory board approvals [12][13][15] - The ESOP is designed to allow employees, including core management, to voluntarily participate, ensuring compliance with the principle of voluntary participation [5][14] Group 2 - The ESOP will be funded through employees' legal salaries, self-raised funds, and other legally permitted means, without the company providing financial assistance or guarantees [5][6] - The total number of shares allocated under the ESOP will not exceed 500,000 shares, representing 0.12% of the company's total equity, with a total funding amount not exceeding 7.965 million yuan [6][8] - The ESOP has a duration of 60 months and a lock-up period of 48 months, with shares vesting in four equal installments [7][8] Group 3 - The management committee will oversee the ESOP, ensuring the protection of participants' rights and compliance with market trading rules [10][11] - The ESOP will not allow forced participation and will adhere to the principle of self-determination for employees [14][15] - The company is required to continuously disclose information regarding the progress of the ESOP in accordance with regulatory requirements [16]